A Fishy Topic: VITAL, REDUCE-IT, STRENGTH, and Beyond: Putting Omega-3 Fatty Acids into Practice in 2021.
Level 5 - mechanism / opinion, no new human data
Narrative review of clinical trials and mechanistic data without systematic review methodology
PubMed 34247311 · doi:10.1007/s11886-021-01527-x
What was done
This narrative review synthesized recent clinical outcome and arteriographic trials (including JELIS, REDUCE-IT, EVAPORATE, VITAL, OMEMI, and STRENGTH) and experimental in vitro data examining the addition of omega-3 fatty acids—specifically purified eicosapentaenoic acid (EPA) versus combination EPA plus docosahexaenoic acid (DHA)—to standard of care therapy for cardiovascular disease risk reduction.
What was found
The abstract reports no numerical data, effect estimates, or statistical values. It qualitatively reports that trials evaluating purified EPA showed reduced cardiovascular disease risk and regression of low attenuation coronary plaque volume, whereas combination EPA/DHA trials failed to demonstrate clinical cardiovascular benefit despite achieving similar triglyceride reductions. In vitro mechanistic data suggested EPA has distinct antioxidant, anti-inflammatory, and membrane-stabilizing properties compared to DHA.
Why it matters
The review synthesizes clinical trial results to argue that purified EPA, rather than combined EPA/DHA formulations, should be preferred for cardiovascular risk reduction in high-risk patients with hypertriglyceridemia.
Limits
This is an unsystematic narrative review rather than a systematic review or meta-analysis. The abstract provides no quantitative metrics, effect sizes, trial sample sizes, or safety data.
Cited by
- context Vascepa is the only omega-3 formulation approved by the FDA for reducing cardiovascular event risk, whereas Lovaza has never been tested in a cardiovascular outcome trial.